Dr. Jeffrey Leiden is the Executive Chairman of Vertex Pharmaceuticals. Dr. Leiden has served as a member of Vertex’s board of directors since 2009 and was President and CEO from 2012 to 2020. Under his leadership, Vertex delivered the first and only precision medicines to treat the underlying cause of cystic fibrosis (CF).
He began his career in academia as a molecular biologist and practicing cardiologist. From 1987 to 2000, Dr. Leiden held several academic and hospital appointments, including roles as Chief of Cardiology, the Rawson Professor of Medicine and Pathology, and an Attending Physician at the University of Chicago; the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health; and Professor of Medicine at Harvard Medical School. During his academic career, he was also involved in starting several biotechnology companies including Vical and Cardiogene. He previously served as President, Chief Operating Officer, and Chief Scientific Officer at Abbott Laboratories and as a Managing Director of Clarus Ventures, a life sciences venture capital firm.
Dr. Leiden is currently the chairman of PathAI and a director of the Massachusetts Mutual Life Insurance Company; chair of the Scientific Advisory Board of the Brigham and Women’s Hospital; and a member of the Scientific Advisory Board of Boston Children’s Hospital. Dr. Leiden also serves as vice chairman of the Massachusetts Competitive Partnership and is on the board of directors of the Boston Private Industry Council, the board of fellows of Harvard Medical School, and co-chairs Massachusetts Governor Charlie Baker’s STEM Advisory Council and Digital Health Council. He received his B.A., M.D. and Ph.D. degrees with honors from the University of Chicago.